Efimosfermin

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis (NASH)

Phase 2

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

CompletedNCT04880031

GlaxoSmithKlineNonalcoholic Steatohepatitis (NASH)

Start: 2021-09-30End: 2025-10-27Updated: 2026-07-08

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

RecruitingNCT06920043

GlaxoSmithKlineMetabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease

Start: 2025-04-09End: 2028-07-10Target: 42Updated: 2026-07-08

Related Papers

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.

2025-06-069 citations